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Abstract
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephropathy by lectin
microarray to identify a biomarker to predict the progression of diabetic nephropathy. Japanese patients with type 2
diabetes at various stages of nephropathy were enrolled and we performed lectin microarray analyses (n = 17) and
measured urinary excretion of fetuin-A (n = 85). The increased signals of urine samples were observed in Siaa2-6Gal/GalNAc-
binding lectins (SNA, SSA, TJA-I) during the progression of diabetic nephropathy. We next isolated sialylated glycoproteins
by using SSA-lectin affinity chromatography and identified fetuin-A by liquid chromatography–tandem mass spectrometer.
Urinary excretion of fetuin-A significantly increased during the progression of albuminuria (A1, 0.4060.43; A2, 0.6060.53; A3
1.5761.13 ng/gCr; p = 7.2961028) and of GFR stages (G1, 0.3960.39; G2, 0.4960.45; G3, 1.2561.18; G4, 1.3460.80 ng/gCr;
p = 3.8961024). Multivariate logistic regression analysis was employed to assess fetuin-A as a risk for diabetic nephropathy
with microalbuminuria or GFR,60 mL/min. Fetuin-A is demonstrated as a risk factor for both microalbuminuria and
reduction of GFR in diabetic nephropathy with the odds ratio of 4.721 (1.881–11.844) and 3.739 (1.785–7.841), respectively.
Collectively, the glycan profiling analysis is useful method to identify the urine biomarkers and fetuin-A is a candidate to
predict the progression of diabetic nephropathy.
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Introduction
The most critical issue in clinical nephrology is relentless and
progressive increase in the patients with end-stage renal disease
(ESRD) in worldwide. The impact of diabetic nephropathy on the
increasing population with chronic kidney disease (CKD) and
ESRD is enormous. The intensified multifactorial intervention in
patients with type 2 diabetes mellitus resulted in reduced risk of
microangiopathy, cardiovascular events and mortality in Steno
type 2 randomized studies [1]; however, the incidence of ESRD is
progressively increasing in worldwide. To predict the progression
of diabetic nephropathy and cardiovascular outcome, the simul-
taneous evaluation of albuminuria and glomerular filtration rate
(GFR) is recommended by the KDIGO: Kidney Disease
Improving Global Outcomes CKD Work Group [2]. In The
Action in Diabetes and Vascular Disease: Preterax and Diami-
cron-MR Controlled Evaluation (ADVANCE) study, the mea-
surements of albuminuria, eGFR or their combination predicted
the cardiovascular events and death, and renal outcome [3]. In
addition to the albuminuria at baseline, the changes of albumin-
uria further well-predicted mortality and cardiovascular and renal
outcomes, independent of baseline albuminuria reported by
ONTARGET investigators [4]. Although the repeated measure-
ments of albuminuria is recommended in the clinical practice in
diabetes, the presence of GFR decliners in both type 1 and type 2
diabetes has been reported. In type 1 diabetes, the GFR decliners
with early reduction of GFR were reported in 9% of the patients
with normoalbuminuria and 31% of microalbuminuria [5]. In the
patients with type 2 diabetes, the rapid GFR decliners demon-
strated the reduction of GFR although they were treated with
olmesartan in addition to the angiotensin converting enzyme
inhibitors. In such patients, it was difficult to predict the natural
course of diabetic nephropathy by the combination of albuminuria
and eGFR [6].
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Based upon these clinical observations, we need to search more
reliable urinary biomarkers to predict both renal and cardiovas-
cular outcome. The biomarkers of renal dysfunction such as
transferrin, type IV collagen and N-acetyl-b-D-glucosaminidase,
Table 1. A list of lectins of LecChipTMVer.1 and the specificity.
Lectin No. Lectin Origin Reported specificity
1 LTL Lotus tetragonolobus Fuc a1-3(Galb1-4)GlcNAc, Fuc a1-2Galb1-4GlcNAc
2 PSA Pisum sativum Fuc a1-6GlcNAc, a-D-Glc, a-D-Man
3 LCA Lens culinaris Fuc a1-6GlcNAc, a-D-Glc, a-D-Man
4 UEA-I Ulex europaeus Fuc a1-2Galb1-4GlcNAc
5 AOL Aspergillus oryzae l-fucose-specific lectin Fuc a1-6GlcNAc (core fucose)
6 AAL Aleuria aurantia Fuc a1-6GlcNAc, Fuc a1-3(Galb1-4)GlcNAc
7 MAL Maackia amurensis Siaa2-3Galb1-4GlcNAc
8 SNA Sambucus nigra Siaa2-6Gal/GalNAc
9 SSA Sambucus sieboldiana Siaa2-6Gal/GalNAc
10 TJA-I Trichosanthes japonica Siaa2-6Gal/GalNAc
11 PHAL Phaseolus vulgaris tri/tetra-antennary complex-type N-glycan
12 ECA Erythrina cristagalli Galb1-4GlcNAc
13 RCA120 Ricinus communis Galb1-4GlcNAc
14 PHAE Phaseolus vulgaris bi-antennary complex-type N-glycan with outer Gal and bisecting GlcNAc
15 DSA Datura stramonium (GlcNAc b1-4)n, Galb1-4GlcNAc
16 GSL-II Griffonia simplicifolia agalactosylated tri/tetra antennary glycans, GlcNAc
17 NPA Narcissus pseudonarcissus High-Mannose, Man a1-6Man
18 ConA Canavalia ensiformis High-Mannose, Man a1-6(Mana1-3)Man
19 GNA Galanthus nivalis High-Mannose, Man a1-3Man
20 HHL Hippeastrum hybrid High-Mannose, Man a1-3Man, Man a1-6Man
21 ACG Agrocybe cylindracea Siaa2-3Galb1-4GlcNAc
22 TxLCI Tulipa gesneriana Man a1-3(Mana1-6)Man, bi- and tri-antennary complex-type N-glycan, GalNAc
23 BPL Bauhinia purpurea alba Galb1-3GalNAc, GalNAc
24 TJA-II Trichosanthes japonica Fuc a1-2Galb1-. or GalNAc b1-. groups at their nonreducing terminals
25 EEL Euonymus europaeus blood group B antigen, Gala1-3Gal
26 ABA Agaricus bisporus Galb1-3GalNAc
27 LEL Lycopersicon esculentum GlcNAc trimers/tetramers
28 STL Solanum tuberosum GlcNAc oligomers, oligosaccharide containing GlcNAc and MurNAc
29 UDA Urtica dioica GlcNAc b1-4GlcNAc, Mixture of Man5 to Man9
30 PWM Phytolacca americana (GlcNAc b1-4)n
31 Jacalin Artocarpus integrifolia Galb1-3GalNAc, GalNAc
32 PNA Arachis hypogaea Galb1-3GalNAc
33 WFA Wisteria floribunda GalNAc b1-4GlcNAc, Galb1-3(-6)GalNAc
34 ACA Amaranthus caudatus Galb1-3GalNAc
35 MPA Maclura pomifera Galb1-3GalNAc, GalNAc
36 HPA Helix pomatia agglutinin a-linked terminal GalNAc
37 VVA Vicia villosa a-linked terminal GalNAc, GalNAc a1-3Gal
38 DBA Dolichos biflorus blood group A antigen, GalNAc a1-3GalNAc
39 SBA Glycine max a- or b-linked termincal GalNAc, GalNAca1-3Gal
40 Calsepa Calystegia sepium Mannose, Maltose
41 PTL-I Psophocarpus tetragonolobus a-linked terminal GalNAc
42 MAH Maackia amurensis Siaa2-3Galb1-3(Siaa2-6)GalNAc
43 WGA Triticum unlgaris chitin oligomers, Sia
44 GSL-I A4 Griffonia simplicifolia Lectin I Isolectin A4 a-linked GalNAc
45 GSL-I B4 Griffonia simplicifolia Lectin I Isolectin B4 a-linked Gal
These data were collected from lectin vendors and reports found by internet searches.
doi:10.1371/journal.pone.0077118.t001
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inflammatory markers including orosomucoid, tumour necrosis
factor-a, transforming growth factor-b, vascular endothelial
growth factor and monocyte chemoattractant protein-1, as well
as oxidative stress markers such as 8-hydroxy-29deoxyguanosine
may be more sensitive than urinary albumin, the current gold
standard, in the detection of incipient nephropathy and risk
assessment of cardiovascular disease; however, the sensitivity of
these markers compared with albumin requires further investiga-
tion [7].
Recently, the urinary proteome analyses have been performed
using 2-dementional gel electrophoresis and subsequent mass
spectrometry to identify the novel urinary markers [8–10];
however, the identification of new markers may be suffered from
contamination of urinary major proteins such as albumin,
immunoglobulins, a1-antitrypsin, transferrin, and haptoglobin.
In the line of considerations, we focused on the alterations of
glycochains to identify useful urinary biomarkers. The changes in
glycoproteome profile in the urine may be due to the alterations in
the glycoprotein leakage into the urine by the damages of capillary
selective permeability and also attributed to the high glucose-
induced changes in the expression of the enzymes which are
responsible to the glycochain modification. For example, increased
hexosamine biosynthesis induced by high glucose conditions plays
a key role in the development of insulin resistance in primary
cultured adipocytes [11] and the increased flux through the
hexosamine biosynthetic pathway and subsequent enhanced O-
linked glycosylation (N-acetylglucosamine [O-GlcNAc]) of pro-
teins have been implicated in insulin resistance in skeletal muscle
[12]. However, the glycoproteome profile has not been well-
investigated because of the technical obstacles. We employed the
evanescent-field fluorescence-assisted lectin microarray: a new
strategy for glycan profiling, which allows sensitive, real-time
observation of multiple lectin-carbohydrate interactions under
equilibrium conditions, to identify the changes in the functional
glycans in a high-throughput manner [13]. We identified the
increase in the biding activity to Siaa2-6-Gal/GalNAc in urine
samples from the patients with diabetic nephropathy. We next
identified fetuin-A, a1-microglobulin, and orosomucoid as sialy-
lated glycoproteins and we found fetuin-A may be a useful urinary
marker to predict the development of microalbuminuria and
reduction of GFR in diabetic nephropathy.
Materials and Methods
Patients
Urine samples of Japanese healthy subjects without type 2
diabetes (n = 12) and Japanese patients with type 2 diabetes with
various stages of normoalbuminuria (n = 7), microalbuminuria
(n = 5) and macroalbuminuria (n = 5) were obtained and subjected
to lectin microarray studies. Based on the lectin microarray
studies, we identified sialylated glycoproteins, such as fetuin-A, a1-
microglobulin, and orosomucoid as candidate markers for diabetic
nephropathy and we newly recruited Japanese patients with type 2
diabetes (n = 85, 62.9611.3 years) into this study. The patients
with type 2 diabetes were treated with oral hypoglycemic agents
(n = 48) and insulin treatment (n = 49). The patients with eGFR
,15 ml/min/1.73 m2 or under dialysis were excluded from the
current study. All recruited patients with type 2 diabetes agreed to
perform lectin microarray of urine samples and measure urinary
levels of fetuin-A, a1-microglobulin, and orosomucoid. The study
was conducted in accordance with the ethical principle of the
Declaration of Helsinki and approved by ethical committee of
Figure 1. Lectin microarray analysis using urine samples from the patients with various albuminuria stages. Lectin microarray analysis
of urine samples were performed in the healthy subjects without type 2 diabetes (Control, n = 12) and the patients with type 2 diabetes with various
stages of normoalubuminuria (A1, n = 7), microalbuminuria (A2, n = 5) and macroalbuminuria (A3, n = 5). Signals to various lectins are compared by
Kruskal-Wallis test.
doi:10.1371/journal.pone.0077118.g001
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Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences. We obtained written informed consent
from each patient.
Lectin Microarray
Fifty mL of urine samples were concentrated by Centricon at
5,000 g for 40 min and further by Microcon at 14,000 g for
70 min to the volume of 0.5 mL (Millipore, Billerica, MA). Ten
mL of concentrated urine samples were applied to Multiple Affinity
Removal Spin Cartridge for Human Serum (Agilent Technologies,
Santa Clara, CA) to remove major serum proteins such as
albumin, IgG, a1-antitrypsin, IgA, transferrin, and haptoglobin.
Five hundred ml of the effluents dialyzed against PBS were applied
to ULTRAFREE 0.5 BIOMAX-5k (Millipore) and concentrated
to final volume of 50 mL. Protein concentration was measured
with MicroBCA Protein Assay Kit (Thermo Scientific Pierce,
Figure 2. SSA-Agarose column choromatography performed in the 4 patients with type 2 diabetes. A. The concentrated urine samples
were applied to SSA-Agarose column, washed with PBS and eluted with 0.2 M lactose. B. The effluents from the patients manifested with various
albuminria and GFR stages, A3G3 and A3G4, were subjected to SDS-PAGE and stained with Coomassie Brilliant Blue. The bands were visualized and
they were subjected to liquid chromatography-tandem mass spectrometer (LC/MS-MS) analysis.
doi:10.1371/journal.pone.0077118.g002
Table 2. Liquid chromatography–tandem mass spectrometer (LC/MS-MS) of samples from the patients with A3G3 and the search
result through NCBInr and Swiss-Prot database performed by Mascot.
Pos. Ac. No. Protein Name Sequences emPAI*1 Score*2
1 ALBU_HUMAN Serum albumin 36 11.04 3985
2 TRFE_HUMAN Serotransferrin 15 1.08 965
3 AMBP_HUMAN Protein AMBP (alpha 1-microglobulin) 5 0.57 224
4 VTDB_HUMAN Vitamin D-binding protein 3 0.14 130
5 HEMO_HUMAN Hemopexin 3 0.23 112
6 PTGDS_HUMAN Prostaglandin-H2 D-isomerase 1 0.18 75
7 IGKC_HUMAN Ig kappa chain C region 1 0.34 70
8 HPT_HUMAN Haptoglobin 3 0.17 63
9 DTX3L_HUMAN E3 ubiquitin-protein ligase DTX3L 1 0.04 49
10 CLUS_HUMAN Clusterin 1 0.07 39
11 SAP_HUMAN Proactivator polypeptide 1 0.06 34
12 A1AT_HUMAN Alpha-1-antitrypsin 2 0.08 33
13 AFAM_HUMAN Afamin 2 0.05 32
14 FETUA_HUMAN Alpha-2-HS-glycoprotein (Fetuin-A) 1 0.09 29
15 THRB_HUMAN Prothrombin 1 0.05 25
16 TRPC4_HUMAN Short transient receptor potential channel 4 1 0.03 20
17 RABE1_HUMAN Q15276 2 0.04 19
18 MARK1_HUMAN Serine/threonine-protein kinase MARK1 1 0.04 16
*1emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute protein amount as follow; emPAI=10 Nobserved/Nobservable21.
*2Probability Based Mowse Score. Ions score is 210*Log(P), where P is the probability that the observed match is a random event. Individual ions scores .16 indicate
identity or extensive homology (p,0.05).
doi:10.1371/journal.pone.0077118.t002
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Rockford, IL) and the final concentration was adjusted to 50 mg/
mL, in which 20 mL was incubated with Cy3 at room temperature
for 1 hour. Cy3-labeled samples were applied to gel filtration
columns (Zeba Desalt Spin Columns 0.5 ml, Thermo Scientific
Pierce) and the samples with 2, 1, 0.5, 0.25, 0.125, 0.063,
0.031 mg/mL were prepared with Probing Buffer and 100 mL/
well of samples were applied to Lectin Array, LecChip (GP
Biosciences, Tokyo, Japan) at 20uC for 15 hours. The lectin signals
were measured with GlycostationTM Reader 1200 with exposure
time (133 msec) and gain (85, 95, 105, and 115). Scanned images
of 16 bit TIFF were analyzed with Array-Pro Analyzer (MEDIA
CYBERNETICS, Rockville, MD) and GlycoStation Tools (GP
Biosciences). The list of lectins is indicated in the Table 1 and
blood group A antigen (HPA) and group B antigen (EEL) were
excluded from the analysis.
Isolation of Sialylated Urinary Proteins in the Patients
with Diabetic Nephropathy
Hundred mL of urine samples were concentrated by Centricon
at 5,000 g for 40 min and further by Microcon at 14,000 g for
70 min to the volume of 1 mL. Affinity chromatography was
performed using SSA-Agarose (Lectin-Agarose Set-III) and
BioLogic LP system II (#731-8300X2, BIO-RAD, Hercules,
CA). The SSA-Agarose column was equilibrated by 6.0 mL of
PBS at the flow rate of 0.2 mL/min. The concentrated urine
samples of 1.0 mL were applied to the sample loop and PBS was
loaded at 0.1 mL/min for 10 min. The SSA-Agarose column was
washed with PBS at 0.1 mL/min for 70 min. Five mL of the
elution buffer (0.2 M lactose) was applied to sample loop and
eluted with PBS at 0.1 mL/min for 60 min and further washed
with PBS at 0.5 mL/min for 20 min. While eluting the sialylated
glycoproteins, the fractions of 0.5 ml were collected every 5 min.
The eluted samples were subjected to SDS-PAGE analysis and the
proteins were identified by Liquid chromatography–tandem mass
spectrometer (LC/MS-MS) analyses as follows.
Cysteine bonds of the eluted glycoproteins were reduced by
10 mM dithiothreitol (DTT) at 56uC for 1 hour and alkylated with
50 mM iodoacetamide (IAA) at room temperature for 45 min in
the dark. They were enzymatically digested with 0.1 mg of
sequencing grade trypsin at 30uC for overnight. The digested
Table 3. Liquid chromatography–tandem mass spectrometer (LC/MS-MS) of samples from the patients with A3G4 and the search
result through NCBInr and Swiss-Prot database performed by Mascot.
Pos. Ac.No. Protein Name Sequences emPAI*1 Score*2
1 ALBU_HUMAN Serum albumin 52 21.13 3829
2 TRFE_HUMAN Serotransferrin 23 1.61 800
3 HPT_HUMAN Haptoglobin 17 3.1 683
4 IGHG1_HUMAN Ig gamma-1 chain C region 10 2.56 601
5 IGHG2_HUMAN Ig gamma-2 chain C region 8 0.99 227
6 IGKC_HUMAN Ig kappa chain C region 6 4.73 516
7 IGHA1_HUMAN Ig alpha-1 chain C region 10 1.54 422
8 A2MG_HUMAN Alpha-2-macroglobulin 18 0.46 417
9 A1AT_HUMAN Alpha-1-antitrypsin 10 1.16 392
10 APOA1_HUMAN Apolipoprotein A-I 8 1.53 251
11 AMBP_HUMAN Protein AMBP (alpha 1-microglobulin) 7 0.88 226
12 HEMO_HUMAN Hemopexin 7 0.62 214
13 LAC2_HUMAN Ig lambda-2 chain C regions 4 1.45 204
14 CO4A_HUMAN Complement C4-A 2 0.04 147
15 CERU_HUMAN Ceruloplasmin 2 0.06 127
16 IC1_HUMAN Plasma protease C1 inhibitor 4 0.22 94
17 A1BG_HUMAN Alpha-1B-glycoprotein 1 0.07 94
18 PTGDS_HUMAN Prostaglandin-H2 D-isomerase 1 0.18 94
19 A1AG1_HUMAN Alpha-1-acid glycoprotein 1 (orosomucoid) 3 0.56 82
20 ANGT_HUMAN Angiotensinogen 1 0.07 74
21 ANT3_HUMAN Antithrombin-III 2 0.07 72
22 KNG1_HUMAN Kininogen-1 2 0.05 71
23 FETUA_HUMAN Alpha-2-HS-glycoprotein (Fetuin-A) 1 0.09 70
24 PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 1 0.06 62
25 CO3_HUMAN Complement C3 5 0.02 55
26 THRB_HUMAN Prothrombin 1 0.05 31
27 VTDB_HUMAN Vitamin D-binding protein 1 0.07 30
28 MTUS1_HUMAN Microtubule-associated tumor suppressor 1 1 0.03 26
*1emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute protein amount as follow; emPAI=10 Nobserved/Nobservable21.
*2Probability Based Mowse Score. Ions score is 210*Log(P), where P is the probability that the observed match is a random event. Individual ions scores .16 indicate
identity or extensive homology (p,0.05).
doi:10.1371/journal.pone.0077118.t003
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peptides were extracted once in 1% formic acid and subsequently
twice in 5% formic acid and in 50% acetonitrite. Peptides were
separated by nanoUPLC (nanoACQUITY UPLC, Waters,
Milford, MA) and analyzed with Q-Tof micro (Waters).
nanoUPLC was equipped with 5.0 mm Symmetry C18,
180 mmID62 cm precolumn and 1.7 mm BEH 130 C18,
100 mmID610 cm column. Mobile phase A was water with
0.1% formic acid whilst mobile phase B was 0.1% formic acid in
acetonitrile. Using MassLynx 4.1 (Waters) the MS/MS raw data
were transformed into peak lists (.pklfiles) and they were searched
thorough NCBInr and Swiss-Prot by using Mascot (Matrix
Science, Boston, MA).
Blood Sampling and Assays
We measured overnight fasting serum levels of total cholesterol,
low density lipoprotein (LDL) cholesterol, high density lipoprotein
(HDL) cholesterol, triglycerides (L Type Wako Triglyceride H,
Wako Chemical, Osaka, Japan), uric acid, creatinine (Cr), and
urea nitrogen (UN). We also measured plasma glucose and
HbA1c. Urinary albumin was measured in random spot urine
samples by standard immuno-nephelometric assay. The urinary
albumin-creatinine ratio (ACR) was calculated. Estimated glomer-
ular filtration rate (eGFR) was calculated by equation; eGFR (ml/
min/1.73 m2) = 1946Cr21.0946age20.287 in male and eGFR (ml/
min/1.73 m2) = 1946Cr21.0946age20.28760.739 in female [14].
By using the definition and classification of chronic kidney disease
[Kidney Disease: Improving Global Outcomes (KDIGO)] [2], all
patients were classified into albuminuria and GFR category. In
albuminuria stages, the patients were classified into three groups;
A1 (,30 mg/gCr), A2 (30–299 mg/gCr) and A3 ($300 mg/gCr).
In GFR stages, they were classified into 4 groups; G1 (.90 ml/
min/1.73 m2), G2 (60–89 ml/min/1.73 m2), G3 (30–59 ml/min/
1.73 m2), and G4 (15–29 ml/min/1.73 m2). Urinary excretions of
fetuin-A, a1-microglobulin, and orosomucoid were measured with
ELISA kit for Human Fetuin-A (BioVender, Modrice, Czech
Republic), LZ Test Eiken a1-M (Eiken Chemical Co., Tokyo,
Japan), and N Antiserum to Human a1-acid Glycoprotein
(Siemens Healthcare Diagnostics Inc., Marburg, Germany).
Statistical Analysis
All data are expressed as mean 6 standard deviation (SD)
values in tables. Urinary levels of fetuin-A, a1-microglobulin, and
orosomucoid demonstrated non-normal distribution and medians
with interquartile range were indicated in box plot in Figures.
Spearman correlation coefficients were used to evaluate whether
urinary levels of fetuin-A, a1-microglobulin, and orosomucoid
correlated with various parameters. To determine the variables
independently associated with urinary levels of fetuin-A, a1-
microglobulin, and orosomucoid in the patients with type 2
diabetes, multiple regression analysis was performed by including
estimated glomerular filtration rate (eGFR), albumin/creatinine
ratio and HDL cholesterol (HDL-C) as independent variables.
Urinary levels of fetuin-A, a1-microglobulin, orosomucoid and
various clinical parameters in albuminuria and GFR stages were
compared by Kruskal-Wallis test. Multivariate logistic regression
analysis to access the urinary fetuin-A, a1-microglobulin, oroso-
mucoid excretions as a risk for diabetic nephropathy with
microalbuminuria or with GFR,60 mL/min. P values less than
Table 4. Comparison of various parameters in albuminuria stages of chronic kidney disease in type 2 diabetes patients (n = 85).
A1 A2 A3 Total Kruskal-Wallis
Number (male/female) 36 (19/17) 25 (15/10) 24 (15/9) 85 (49/36)
Age (years) 63.8611.3 61.0612.5 63.3612.3 62.9611.3 0.006*
BMI (kg/m2) 24.865.1 25.764.5 24.263.9 24.964.6 0.543
SBP (mmHg) 124.0612.6 129.5620.5 126.0619.7 126.2617.3 0.484
DBP (mmHg) 73.9610.3 72.668.1 69.1614.4 72.2611.1 0.261
HbA1c (%) 7.3160.64 7.2460.90 7.3861.17 7.3160.87 0.850
Total protein (g/L) 70.464.3 70.764.8 66.166.5 69.365.4 0.003*
Albumin (g/L) 42.962.5 41.263.2 35.767.0 40.465.3 1.80610216**
Cr (mmol/L) 66.4613.3 78.3626.3 144.2670.3 91.9652.3 4.86610210**
UN (mmol/L) 5.561.5 7.162.7 10.063.8 7.363.3 5.9261028**
Uric acid (mmol/L) 305.8661.5 352.8696.2 396.2668.0 344.6683.1 9.6861025**
T-Cho (mmol/L) 5.0960.94 4.8660.84 5.0661.14 4.9960.97 0.689
TG (mmol/L) 1.6560.92 1.7061.10 2.1661.74 1.8161.26 0.780
HDL-C (mmol/L) 1.4960.41 1.3560.31 1.2360.39 1.3860.39 0.031*
LDL-C (mmol/L) 2.8560.81 2.7060.65 2.8060.95 2.7960.80 0.271
eGFR (mL/min) 74.5616.3 67.9619.2 42.4619.0 63.5622.4 6.6661029**
ACR (mg/gCr) 12.766.0 114.3672.6 14246996 441.26812 1.81610216**
Fetuin-A (ng/gCr) 0.4060.43 0.6060.53 1.5761.13 0.7960.87 7.2961028**
a1-microglobulin (mg/gCr) 4.2464.03 6.3065.12 17.83618.08 8.68611.74 8.8461029**
Orosomucoid (ng/gCr) 17.569.1 17.968.7 91.4687.2 38.5657.0 3.3461028**
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG,
Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin/creatinine ratio;
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0077118.t004
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0.05 were considered statistically significant. Statistical analysis
was performed with IBM SPSS Statistics Base and IBM SPSS
Regression (IBM, Armonk, NY).
Results
Lectin Microarray Analyses Demonstrated the Increased
Binding Activity to Siaa2-6-Gal/GalNAc
We performed lectin microarray analyses and compared the
urine samples of the healthy subjects without type 2 diabetes
(n = 12) and the patients with type 2 diabetes with various stages of
normoalubuminuria (n = 7), microalbuminuria (n = 5) and macro-
albuminuria (n = 5). The reactivity to the many lectins, such as
fucose binder (PSA, LCA, AOL, and AAL), Lac/LacNAc binder
[PHA(L), ECA, RCA120, PHA(E)], a- or b-Gal binder (BPL,
ABA, PNA, ACA), chitobiose binder (DSA, LEL, STL, UDA,
PWM, WGA), and a- or b-GalNAc binder (Jacalin, WFA, MPA,
VVA, DBA, SBA, PTL-I, GSL-IA4), significantly declined at the
stage of macroalbuminuria (Figure 1). Among them, lectins
which bind to N-glycosylation, RCA120, PHA(E), DSA, demon-
strated the increased binding activity at the stage of microalbu-
minuria. Notably, in contrast to majority of the lectins, the binding
to Siaa2-6-Gal/GalNAc (SNA, SSA, TJA-1) progressively in-
creased in the albuminuria stages of diabetic nephropathy
(Figure 1, red box). Since we identified specific increase in the
biding activity to Siaa2-6-Gal/GalNAc in urine samples in the
patients with diabetic nephropathy, we next screened the sialylated
glycoproteins in the urine samples of diabetic nephropathy.
Fetuin-A, a1-microglobulin and Orosomuioid were
Identified by SSA-Agarose Column Chromatography and
LC/MS-MS Analyses
SNA- and SSA-agarose were commercially available and we
could isolate the glycoproteins by SSA-agarose in preliminary
experiments. Thus, we performed SSA-Agarose column chor-
omatography and the effluents were subjected to SDS-PAGE in
Figure 3. Urinary excretion of fetuin-A, a1-microglobulin, orosomucoid and albumin creatinine ratio (ACR) in various stages of
diabetic nephropathy (n=85). All of the urinary excretion of sialylated glycoprpteins such as fetuin-A, a1-microglobulin, and orosomucoid are
compared by Kruskal-Wallis test.
doi:10.1371/journal.pone.0077118.g003
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Figure 2. We confirmed that the bands visualized with Coomassie
Brilliant Blue staining increased in the patients with CKD stage of
A3G4 compared with the patients A3G3. The effluents were
subjected to LC/MS-MS and raw data of the proteins hit by
Mascot program searching through NCBInr and Swiss-Prot
database were indicated in Tables 2 and 3 in the patients with
CKD stages of A3G3 and A3G4, respectively. The listed proteins
demonstrated the serum major proteins such as albumin,
immunoglobulins, complements, a1-antitrypsin, transferrin, and
haptoglobin. However, we identified three sialylated glycoprpteins
such as a1-microglobulin (Protein AMBP), a1-acid glycoprotein
(orosomucoid) and fetuin-A (a2-HS-glycorptein). Fetuin-A [15],
a1-microglobulin [16], and orosomucoid [17] have been reported
as sialylated glycoproteins and we further validated the signifi-
cance of urinary excretion of sialylated glycoproteins as biomark-
ers for diabetic nephropathy.
Elevated Urinary Fetuin-A Excretion is a Risk for the
Development of Diabetic Nephropathy
We investigated urinary excretion of sialylated glycoproteins in
various stages of diabetic nephropathy (n= 85). In albuminuria
stages, age, serum total protein, serum albumin, Cr, UN, uric acid,
HDL-C, eGFR, ACR were significantly changed revealed by
Kruskal-Wallis test (Table 4). All of the urinary excretion of
sialylated glycoprpteins such as fetuin-A, a1-microglobulin, and
orosomucoid significantly increased during the progression of A1
to A3 stages (Table 4 and Figure 3a–d). During the progression
of GFR stages, serum total protein, serum albumin, Cr, UN, uric
acid, eGFR, and ACR were significantly altered by Kruskal-Wallis
test (Table 5). Like albuminuria stages, the urinary excretion of
fetuin-A, a1-microglobulin, and orosomucoid significantly in-
creased in the GFR stages from G1 to G4 revealed by Kruskal-
Wallis test (Table 5 and Figure 3e–h).
All of the urinary excretion of fetuin-A, a1-microglobulin, and
orosomucoid positively correlated with Cr, UN and ACR and
negatively correlated with serum albumin, HDL-C and eGFR
with statistically significant differences (Table 6 and Figure 4).
The linear regression analyses were followed by a multiple
regression analysis using the urinary excretion of fetuin-A, a1-
microglobulin, and orosomucoid as the dependent variables to
further analyze the significant predictors (Table 6). eGFR, ACR
and HDL-C were used as independent variables. eGFR and ACR
independently and significantly predicted urinary excretion of
fetuin-A and a1-microglobulin. For urinary excretion of oroso-
mucoid, ACR and HDL-C were significantly determinants in
multiple regression models in Table 7. Finally, multivariate
logistic regression analysis was employed to assess three urinary
sialylated glycoproteins as a risk for diabetic nephropathy with
microalbuminuria or GFR,60 mL/min. We used the forward
stepwise method and the variable whose addition causes the largest
statistically significant change in 22 Log Likelihood is added to
the model. The final models are indicated in Tables 8 and only
fetuin-A was demonstrated as a risk factor for both microalbu-
minuria and reduction of GFR in diabetic nephropathy with the
odds ratio (95% confidence intervals) of 4.721 (1.881–11.844) and
3.739 (1.785–7.841), respectively.
Table 5. Comparison of various parameters in glomerular filtration stages of chronic kidney disease in type 2 diabetes patients
(n = 85).
G1 G2 G3 G4 Total Kruskal-Wallis
Number (male/female) 9 (6/3) 42 (22/20) 29 (19/10) 5 (2/3) 85 (49/36)
Age (years) 51.9613.9 62.9610.3 66.569.2 59.6615.3 62.9611.3 0.647
BMI (kg/m2) 27.668.1 25.164.6 24.163.1 22.662.2 24.964.6 0.155
SBP (mmHg) 129.7613.8 127.6617.3 124.0619.1 120.2611.1 126.2617.3 0.640
DBP (mmHg) 76.5613.8 74.668.0 69.5612.4 59.469.2 72.2611.1 0.006
HbA1c (%) 7.5460.79 7.2760.83 7.4060.94 6.6860.82 7.3160.87 0.323
Total protein (g/L) 70.463.7 70.964.4 67.666.2 63.065.0 69.365.44 0.002*
Albumin (g/L) 41.464.6 42.362.9 38.366.6 33.465.0 40.465.3 1.1061024**
Cr (mmol/L) 60.9616.0 65.9611.6 115.7640.7 227.1688.2 91.9652.3 1.89610217**
UN (mmol/L) 5.562.2 5.861.6 8.662.7 14.665.1 7.363.3 9.85610212**
Uric acid (mmol/L) 329.1639.5 312.8674.4 388.7682.6 391.4699.8 344.6683.1 6.5961024**
T-Cho (mmol/L) 5.1160.96 4.9760.89 5.0661.02 4.5261.39 4.9960.97 0.695
TG (mmol/L) 2.0461.30 1.6861.06 1.9561.57 1.5860.63 1.8161.26 0.487
HDL-C (mmol/L) 1.2560.26 1.4460.37 1.3260.41 1.4560.51 1.3860.39 0.427
LDL-C (mmol/L) 2.9660.95 2.7960.67 2.8360.92 2.2860.87 2.7960.80 0.740
eGFR (mL/min) 96.2615.6 74.868.1 44.469.2 20.668.3 63.5622.4 1.16610230**
ACR (mg/gCr) 179.76451.6 108.36227.7 824.560.80 148461168 441.26812 1.0961025**
Fetuin-A (ng/gCr) 0.3960.39 0.4960.45 1.2561.18 1.3460.80 0.7960.87 3.8961024**
a1-microglobulin (mg/gCr) 3.7464.26 4.9464.92 11.90611.04 30.32629.93 8.68611.74 2.4961026**
Orosomucoid (ng/gCr) 22.5611.4 19.7614.8 62.7684.3 84.4669.4 38.5657.0 2.2161023**
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG,
Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin/creatinine ratio;
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0077118.t005
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Table 6. Simple correlation of urinary sialylated glycoprotein excretions with various clinical parameters in the patients with type 2
diabetes (n = 85).
Fetuin-A (ng/gCr) a1-microglobulin (mg/gCr) Orosomucoid (ng/gCr)
Age (years) R = 0.009, p = 0.937 R= 0.123, p = 0.261 R =20.008, p = 0.944
BMI (kg/m2) R =20.139, p = 0.205 R=20.067, p = 0.541 R =20.032, p = 0.770
SBP (mmHg) R = 0.043, p = 0.693 R=20.005, p = 0.964 R = 0.103, p = 0.348
DBP (mmHg) R =20.145, p = 0.186 R=20.214, p = 0.049* R =20.027, p = 0.807
HbA1c (%) R = 0.113, p = 0.307 R= 0.110, p = 0.318 R = 0.056, p = 0.612
Total protein (g/L) R =20.261, p = 0.017* R =20.275, p = 0.012* R =20.213, p = 0.053
Albumin (g/L) R =20.377, p = 4.3661024** R =20.376, p = 4.6761024** R =20.394, p = 2.2861024**
Cr (mmol/L) R = 0.368, p = 5.2361024** R = 0.388, p = 2.4061024** R = 0.399, p = 1.5361024**
UN (mmol/L) R = 0.405, p = 1.3161024** R = 0.439, p = 2.9661025** R = 0.363, p = 6.8561024**
Uric acid (mmol/L) R = 0.079, p = 0.474 R= 0.073, p = 0.509 R = 0.295, p = 0.006**
T-Cho (mmol/L) R =20.099, p = 0.372 R=20.080, p = 0.471 R = 0.062, p = 0.576
TG (mmol/L) R = 0.060, p = 0.582 R= 0.055, p = 0.615 R = 0.186, p = 0.088
HDL-C (mmol/L) R =20.313, p = 0.004** R =20.258, p = 0.017* R =20.244, p = 0.025*
LDL-C (mmol/L) R =20.007, p = 0.948 R=20.043, p = 0.697 R = 0.067, p = 0.544
eGFR (mL/min) R =20.395, p = 1.8061024** R =20.472, p = 5.2361026** R =20.431, p = 3.9061025**
ACR (mg/gCr) R = 0.548, p = 5.7661028** R = 0.466, p = 7.0261026** R = 0.652, p = 1.40610211**
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG,
Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin/creatinine ratio;
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0077118.t006
Figure 4. Simple correlation of urinary excretion of fetuin-A, a1-microglobulin, orosomucoid with estimated glomerular filtration
ratio (eGFR) and urinary albumin creatinine ratio (ACR) in the patients with diabetic nephropathy (n=85). Spearman correlation
coefficients are used to evaluate whether urinary levels of fetuin-A, a1-microglobulin, and orosomucoid correlate with eGFR and ACR.
doi:10.1371/journal.pone.0077118.g004
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Discussion
Glycans have important roles in living organisms with their
structural diversity; however, glycan profiling studies have not
been extensively performed because it is technically challenging.
Recently, the genome-wide association study identified hepatocyte
nuclear factor 1-a (HNF1A) as a key regulator of fucosylation and
the DG9-glycan index, which is the ratio of fucosylated to
nonfucosylated triantennary glycans, display altered fucosylation
of N-linked glycans on plasma proteins. Thus, the glycan
biomarkers could improve the efficiency of a diagnosis of
HNF1A-MODY [18]. In diabetic nephropathy, Ahn J.M. et al.
performed glycan profile of plasma samples from normal subjects
and the patients with diabetes. They captured glycoproteins by
multi-lectin affinity chromatography and trypsin-digested glyco-
proteins were subjected to the analysis by LC-MS/MS [19].
However, no other studies have been reported to survey the glycan
profile of the urine samples so far, and we believe that the current
investigation is the first study to perform glycan profiling of urines
samples from the patients with diabetic nephropathy. As a result,
we have found that global reduction of the bindings to lectins, such
as fucose, Lac/LacNA, a- or b-Gal, chitobiose, and a- or b-
GalNAc binders in urine samples of diabetic nephropathy at
macroalbuminuria stage. Unlike the reduced bindings to these
lectins, the biding activity to Siaa2-6-Gal/GalNAc binders
progressively increased at micro- and macroalbuminruia stages.
In the patients with type 1 diabetes, the reduction of sialidase
activities was observed in mononuclear leucocytes and they
speculated that diabetes-associated changes in sialylation of
functional cell surface glycolconjugates may have important
clinical consequences in diabetes [20]. The analysis of sialylation
of insulin-like growth factor-binding protein (IGFBP)-3 from the
poorly controlled patients with type 2 diabetes, increased binding
of IGFBP-3 to SNA suggesting increased sialylation of IGFBP3
[21]. In contrast, reduced a2-6 sialylation of glycodelin-A was
observed in gestational diabetes mellitus [22]. One can speculate
that the alterations in the expression of sialyltransferases or
sialidase may influence the sialylation of plasma glycoproteins;
however, the status of sialylation seems to be complex in the
patients with diabetes. Increased sialylated glycoproteins in urine
samples may also be due to the alteration in the permselectivities
of glomerular capillary, since sialylated glycoproteins are charac-
terized by negative charge.
a1-microglobulin, also known as protein HC (for Heteroge-
neous Charge), was initially suggested as a marker for the detection
of proximal tubular dysfunction by cadmium poisoning [23]. a1-
microglobulin is a small protein with up to 31 kDa and it is filtered
through glomeruli and reabsorbed by the proximal tubules [24].
Urinary excretion of a1-microglobulin was significantly higher in
Table 7. Multiple linear regression analysis using urinary sialylated glycoprotein excretions as dependent variables in the patients
with type 2 diabetes (n = 85).
Dependent variable Independent variable
Unstandardized
coefficient
Standardized
coefficient t value P value Adjusted R2
B
Standard
Error Beta
Fetuin-A eGFR (mL/min) 20.076 0.042 20.196 21.813 0.074 0.335
(ng/gCr) ACR (mg/gCr) 0.004 0.001 0.395 3.645 4.7161024**
HDL-C (mmol/L) 24.048 2.035 20.182 21.989 0.050
a1-microglobulin eGFR (mL/min) 20.138 0.053 20.263 22.617 0.011* 0.423
(mg/gCr) ACR (mg/gCr) 0.007 0.001 0.461 4.560 4.7161025
HDL-C (mmol/L) 21.443 2.548 20.048 20.566 0.573
Orosomucoid eGFR (mL/min) 20.136 0.212 20.053 20.642 0.523 0.605
(ng/gCr) ACR (mg/gCr) 0.049 0.006 0.703 8.405 1.19610212**
HDL-C (mmol/L) 226.65 10.240 20.183 22.603 0.011
Estimated glomerular filtration rate (eGFR), albumin/creatinine ratio and HDL cholesterol (HDL-C) are used as independent variables in stepwise multiple linear
regression analysis in model 1. In model 2, all parameters are included in the analysis.
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0077118.t007
Table 8. Stepwise multivariate logistic regression analysis to assess the urinary sialylated glycoprotein excretions as a risk for
diabetic nephropathy with microalbuminuria or glomerular filtration rate (GFR),60 ml/min.
Risk factor for microalbuminuria B Standard error p
Odds ratio (95% confident
intervals) Predictive accuracy
Fetuin-A (ng/gCr) (1SD increments) 1.784 0.539 9.42461024** 4.721 (1.881–11.844) 74.1%
Risk factor for GFR,60 mL/min B Standard error p Odds ratio (95% confident
intervals)
Predictive accuracy
Fetuin-A (ng/gCr) (1SD increments) 1.516 0.434 4.75561024** 3.739 (1.785–7.841) 72.9%
**p,0.01.
doi:10.1371/journal.pone.0077118.t008
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the early stages of the disease process, while albumin excretion was
still in the normal range [25]. Thus, it may serves as early marker
for tubular damages in diabetic nephropathy and may precede
albumin excretion to the urine [25–27]. Low molecular weight
markers of tubular dysfunction such as a1-microglobulin, there-
fore, appear as markers of renal dysfunction that may complement
markers of glomerular dysfunction such as albumin [7]. Oroso-
mucoid, a-1 acid glycoprotein with 41 kDa, is an acute-phase
protein and the serum concentrations correlated with low-grade
inflammation in the patients with diabetes [28,29]. Urine
excretion of orosomucoid was increased in the patients with
diabetes and normoalbuminuria and it correlated with markers of
inflammation such as CRP [29–31] and markers for endothelial
dysfunction [32]. Type 2 diabetic patients with elevated urinary
orosomucoid excretion exhibited normal glomerular and tubular
function, suggesting the possibility of local renal production of
orosomucoid due to chronic low-grade inflammation rather than
hyperfiltration [33].
Fetuin-A has been principally studied as an inhibitor for ectopic
calcium deposition in the renal field and it is also an important
promoter for insulin resistance. Fetuin-A, a liver secretory
glycoprotein with 64 kDa, has been shown that it acts as carrier
of free fatty acids (FFAs) and they are the intrinsic ligands for Toll-
like receptor 4 (TLR4), which induces adipose tissue inflammation
and insulin resistance [34]. Fetuin-A binds to the residues of
Leu100-Gly123 and Thr493-Thr516 of TLR4 through the
terminal galactoside moiety [34]. Thus, FFA-Fetuin-A induced
TLR4 activation is very important in the lipid-induced inflam-
mation and insulin resistance and type 2 diabetes. In addition,
fetuin-A and adiponectin mediate the crosstalk between adipose
tissues, liver and kidney. Fetuin-A suppresses mRNA expression of
adiponectin in cultured human adipocytes and treatment of wild-
type mice with fetuin-A lowered serum adiponectin levels [35].
Higher fetuin-A and lower adiponectin levels may contribute the
development of insulin resistance, diabetes and subsequent
obesity-related CKD and diabetic nephropathy [36]. Serum
concentration of fetuin-A in type 2 diabetes patients has been
reported and they positively correlated with macrovascular late
complications in high-risk type 2 diabetes patients, while no
association with metabolic status or microvascular complications
[37]. Recent study indicated that serum fetuin-A is lower in
microalbuminuria patients compared with normo- and mascroal-
buminuric patients [38]. In other studies, lower serum levels of
fetuin-A are associated with peripheral arterial disease in patients
with type 2 diabetes [39] and serum fetuin-A levels are negatively
associated with atherosclerotic calcified plaques [40]. Thus, the
significance of serum fetuin-A levels is controversial whether it is a
good marker for diabetic micro- and macrovascular complications.
Unfortunately, we failed to detect changes in binding activities to
various lectins in the sera from the patients with various stages of
diabetic nephropathy (data not shown), we did not get a chance to
measure the serum levels of fetuin-A. However, we demonstrated
that the urinary excretion of fetuin-A is a candidate for the
biomarker to predict the progression of diabetic nephropathy.
Although two previous published studies identified fetuin-A in
urines samples of the patients with diabetic nephropathy, the
quantifications were limited to inaccurate estimations by fluores-
cence 2-D differential in-gel electrophoresis [41] and capillary
electrophoresis coupled to mass spectrometry [42]. In contrast to
previous studies, we firstly used stable ELISA kit to quantify the
urinary excretion of fetuin-A. Urinary concentration of fetuin-A
may be depending on the production from the liver, alterations in
permeability through glomerular basement membrane by capillary
damages and changes in tubular reabsorption. Higher excretion of
fetuin-A into urine has been reported to reflect the insulin
resistance and inflammatory responses in obesity and type 2
diabetes [43] and it may reflect the increase in the serum levels of
fetuin-A and alterations in the changes in the permeability of
glomerular capillaries. Fetuin-A is reported to pass through the slit
diaphragm and re-introduced to proximal tubular cells by
megalin-mediated endocytosis [44]. Zhou et al. also reported that
urinary exosomal fetuin-A was increased in the rats treated with
cisplatin injection and in the ICU patients with acute kidney injury
[45]. Thus, an alternative explanation for increased urinary fetuin-
A excretion in diabetic nephropathy could be due to the tubular
injury. In our study, multivariate regression analysis indicated that
higher urinary fetuin-A excretion demonstrated a higher risk for
the development of microalbuminuria and reduction of renal
function and future cohort study is required to further confirm this
notion.
Conclusions
In summary, the glycan profiling studies using urine samples
from the patients with diabetic nephropathy is useful to identify
the new biomarkers to predict the progression of diabetic
nephropathy. We demonstrated that global reduction of the
bindings to lectins, such as fucose, Lac/LacNA, a- or b-Gal,
chitobiose, and a- or b-GalNAc binders in urine samples of
diabetic nephropathy at macroalbuminuria stage, and in contrast
increased biding activity to Siaa2-6-Gal/GalNAc binders. Fur-
ther, we identified three sialylated glycoprpteins such as a1-
microglobulin (Protein AMBP), a1-acid glycoprotein (orosomu-
coid) and fetuin-A (a2-HS-glycorptein) by SSA-Agarose column
choromatography and LC/MS-MS analysis. Finally, we have
newly shown that higher urinary excretion of fetuin-A is a risk
factor for both microalbuminuria and reduction of GFR in
diabetic nephropathy.
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